Zaidel Ezequiel J, Wyss Quintana Fernando S, Sosa Liprandi Álvaro, Mendoza Iván, Márquez Manlio F, Nuñez Elaine, Barbosa Marcia, Baranchuk Adrián
Grupo de Trabajo COVID-19 de la Sociedad Interamericana de Cardiología. E-mail:
Grupo de Trabajo COVID-19 de la Sociedad Interamericana de Cardiología.
Medicina (B Aires). 2020;80(3):271-274.
Due to the coronavirus disease 2019 (COVID-19) pandemic, a wide number of compounds are under scrutiny regarding their antiviral activity, one of them being hydroxychloroquine. Cardiac aspects of the use of chloroquine and hydroxychloroquine are reviewed in this manuscript. A non-systematic review of the medical literature was performed. Information about their safety and efficacy as antimalarials, antivirals, as well as in the long-term treatment of rheumatic diseases was collected. We found an anti-inflammatory effect with reduction of longterm cardiovascular events, a very infrequent heart disease due to a lysosomal effect of the drug, and at the hemodynamic level hypotension, tachycardia, and QT interval prolongation, exacerbated when combined with azithromycin. However, the rate of adverse cardiac events of hydroxychloroquine (and chloroquine) was low.
由于2019冠状病毒病（COVID-19）大流行，大量化合物因其抗病毒活性而受到审查，其中之一是羟氯喹。本文对氯喹和羟氯喹使用的心脏方面进行了综述。对医学文献进行了非系统性综述。收集了有关它们作为抗疟药、抗病毒药以及在风湿性疾病长期治疗中的安全性和有效性的信息。我们发现其具有抗炎作用，可减少长期心血管事件，因药物的溶酶体效应导致的心脏病非常罕见，在血流动力学方面有低血压、心动过速和QT间期延长，与阿奇霉素合用时会加剧。然而，羟氯喹（和氯喹）的不良心脏事件发生率较低。
